Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin

AAPS Journal

Volumn 16, Issue 5, 2014, Pages 1077-1084

  Parrott, Neil ^a   Hainzl, Dominik ^a   Scheubel, Emmanuel ^b   Krimmer, Siegfried ^b   Boetsch, Christophe ^b   Guerini, Elena ^b   Martin Facklam, Meret ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

absorption model; bitopertin; formulation; glycine reuptake inhibitor; glycine transporter 1; physiologically based pharmacokinetics; quality by design; RG1678

Indexed keywords

BITOPERTIN; (4-(3-FLUORO-5-TRIFLUOROMETHYLPYRIDIN-2-YL)PIPERAZIN-1-YL)(5-METHANESULFONYL-2-(2,2,2-TRIFLUORO-1-METHYLETHOXY)PHENYL)METHANONE; MICROCAPSULE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; SOLUTION AND SOLUBILITY; SULFONE; TABLET;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSICAL CHEMISTRY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANIMAL MODEL; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; COMPUTER SIMULATION; INTESTINE ABSORPTION; MACACA FASCICULARIS; MEDICINAL CHEMISTRY; MICROCAPSULE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLUBILITY; SOLUTION AND SOLUBILITY; STOMACH ABSORPTION; TABLET; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; FEMALE; GASTRIC ABSORPTION; HUMANS; INTESTINAL ABSORPTION; MACACA FASCICULARIS; MALE; MIDDLE AGED; MODELS, ANIMAL; MODELS, BIOLOGICAL; PARTICLE SIZE; PHARMACEUTICAL SOLUTIONS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOLUBILITY; SULFONES; TABLETS; YOUNG ADULT;

EID: 84908356025     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9639-y     Document Type: Article

References (24)

1. Agoram B, Woltosz WS, et al . Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50(Supplement 1):S41-67. (Pubitemid 32905355)
2. Alberati D, Moreau J-L, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62(2):1152-61.
3. Cheeti S, Budha NR, et al. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos. 2013;34:141-54.
4. Department of Heath and Human Services, U. S. F. a. D. A. 2007 Pharmaceutical Quality for the 21st Century A Risk-Based Approach Progress Report. http://www.fda.gov/aboutfda/ centersof fi ces/of fi ceofmedicalproductsandtobacco/cder/ ucm128080.htm. Accessed 12 Jan 2014
5. Galia E, Nicolaides E, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and class II drugs. Pharm Res. 1998;15:698-705. (Pubitemid 28275645)
6. Hyman SE. A glimmer of light for neuropsychiatric disorders. Nature. 2008;455(7215):890-3.
7. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Current Opin Drug Discov Dev. 2009;12(4):468.
8. Javitt DC. Glutamate and Schizophrenia: phencyclidine, N-Methyl- d-Aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69-108. Academic Press.
9. Jiang W, Kim S, et al. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int J Pharm. 2011;418(2):151-60.
10. Juran JM. Juran on quality by design: the new steps for planning quality into goods and services: planning, setting and reaching quality goals the free press. A division of Simon and Schuster Inc; 1992.
11. Kuentz M. Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J. 2008;10(3).
12. Kuentz M, Nick S, et al. A strategy for preclinical formulation development using GastroPlusTM as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci. 2006;27:91-9. (Pubitemid 41728259)
13. Lu ATK, Frisella ME, et al . Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res. 1993;10(9).
14. Malvern. Mastersizer 2000. http://www.malvern.com/en/products/ product-range/mastersizer-range/mastersizer-2000/default.aspx. Accessed 27 Feb 2014
15. Mathias NR, Crison J. The use of modeling tools to drive efficient oral product design. Aaps Journal. 2012;14(3):591- 600.
16. Noyes AS, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19:930 - 4.
17. Parrott N, Hainzl D, et al. Physiologically based pharmacokinetic modelling to predict single and multiple dose human pharmacokinetics of bitopertin. Clin Pharmacokinet. 2013;52(8):673-83.
18. Parrott N, Lave T. Applications of physiologically based absorption models in drug discovery and development. Mol Pharm. 2008;5(5):760- 75.
19. Parrott N, Lave T. Computer models for predicting drug absorption. Oral Drug Absorption. J Dressman and C. Reppas, Informa. 2010.
20. Pinard E, Alanine A, et al. Selective GlyT1 inhibitors: discovery of [4-(3- fl uoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5- methanesulfonyl-2-((S)-2,2,2-tri fl uoro-1-methylethoxy) phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem. 2010;53(12):4603-14.
21. Rowland M, Peck C, et al. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51(1):45 -73.
22. Sympatec GmbH. " Sympatec HELOS " http://www.sympatec.com/EN/ LaserDiffraction/HELOS.html. Accessed 1 Feb 2014
23. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781-91.
24. Zhang X, Lionberger RA, et al. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J. 2011;13(1).